製品の概要
-
製品名Anti-Prosurfactant Protein C antibody
Prosurfactant Protein C 一次抗体 製品一覧 -
製品の詳細Rabbit polyclonal to Prosurfactant Protein C
-
由来種Rabbit
-
アプリケーション適用あり: WBmore details
-
種交差性交差種: Mouse, Human
-
免疫原
Synthetic peptide conjugated to KLH derived from within residues 100 to the C-terminus of Human Prosurfactant Protein C.
-
ポジティブ･コントロール
- This antibody gave a positive signal in human and mouse lung tissue lysates.
製品の特性
-
製品の状態Liquid
-
保存方法Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C or -80°C. Avoid freeze / thaw cycle.
-
バッファーpH: 7.40
Preservative: 0.02% Sodium azide
Constituents: 1% BSA, PBS -
Concentration information loading... -
精製度Immunogen affinity purified
-
ポリ/モノポリクローナル
-
アイソタイプIgG
-
研究分野
関連製品
-
Compatible Secondaries
-
Positive Controls
アプリケーション
Our Abpromise guarantee covers the use of ab101251 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
| アプリケーション | Abreviews | 特記事項 |
|---|---|---|
| WB | Use a concentration of 1 µg/ml. Detects a band of approximately 25 kDa (predicted molecular weight: 21 kDa). |
ターゲット情報
-
機能Pulmonary surfactant associated proteins promote alveolar stability by lowering the surface tension at the air-liquid interface in the peripheral air spaces.
-
関連疾患Defects in SFTPC are the cause of pulmonary surfactant metabolism dysfunction type 2 (SMDP2) [MIM:610913]; also called pulmonary alveolar proteinosis due to surfactant protein C deficiency. A rare disease associated with progressive respiratory insufficiency and lung disease with a variable clinical course, due to impaired surfactant homeostasis. It is characterized by alveolar filling with floccular material that stains positive using the periodic acid-Schiff method and is derived from surfactant phospholipids and protein components. Excessive lipoproteins accumulation in the alveoli results in severe respiratory distress.
Genetic variations in SFTPC are a cause of susceptibility to respiratory distress syndrome in premature infants (RDS) [MIM:267450]; also known as RDS in prematurity. RDS is a lung disease affecting usually premature newborn infants. It is characterized by deficient gas exchange, diffuse atelectasis, high-permeability lung edema and fibrin-rich alveolar deposits called 'hyaline membranes'. -
配列類似性Contains 1 BRICHOS domain.
-
細胞内局在Secreted > extracellular space > surface film.
- Information by UniProt
-
参照データベース
- Entrez Gene: 6440 Human
- Entrez Gene: 20389 Mouse
- Omim: 178620 Human
- SwissProt: P11686 Human
- SwissProt: P21841 Mouse
- Unigene: 1074 Human
- Unigene: 24040 Mouse
-
別名
- BRICD6 antibody
- BRICHOS domain containing 6 antibody
- PSP C antibody
see all
画像
-
Western blot - Anti-Prosurfactant Protein C antibody (ab101251)All lanes : Anti-Prosurfactant Protein C antibody (ab101251) at 1 µg/ml
Lane 1 : Lung (Human) Tissue Lysate
Lane 2 :Mouse lung normal tissue lysate - total protein (ab29297)
Lysates/proteins at 10 µg per lane.
Secondary
All lanes : Goat Anti-Rabbit IgG H&L (HRP) preadsorbed (ab97080) at 1/5000 dilution
Developed using the ECL technique.
Performed under reducing conditions.
Predicted band size: 21 kDa
Observed band size: 25 kDa (why is the actual band size different from the predicted?)
Additional bands at: 22 kDa. We are unsure as to the identity of these extra bands.
Exposure time: 3 minutes
Prosurfactant Protein C contains a number of potential glycosylation sites (SwissProt) which may explain its migration at a higher molecular weight than predicted.
プロトコール
参考文献
ab101251 has not yet been referenced specifically in any publications.
レビューと Q&A
Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"